Case Report: Generalized lipodystrophy following immune-checkpoint inhibitor therapy.

Andrew-Hyun Lee1,2, Rina Hui2,3, Jenny E Gunton1,2,4

  • 1Department of Diabetes and Endocrinology, Westmead Hospital, Sydney, NSW, Australia.

PubMed
Summary

Immune checkpoint inhibitors (ICI) can cause lipodystrophy, a rare fat loss condition. This case highlights a patient developing severe lipodystrophy after pembrolizumab treatment for breast cancer.